Treatment of acute diarrhoea
What is Tasectan
Tasectan® AF is a substance-based medical device composed of xyloglucan (tamarind seed extract) and gelose. This combination acts by forming a film that protects the intestinal mucosa, reducing the frequency and duration of diarrhoeal episodes. The therapeutic effects of the device start from 6 hours after ingestión.
Intended Use
Tasectan® AF is specifically formulated for the reduction and control of symptoms related to diarrhoeal episodes of different aetiologies, such as frequent liquid or soft stools and abdominal discomfort.
Who is Tasectan® AF for
Tasectan® AF is approved for use, at different dosages, in children under 3 years up until 14 years (sachets); and in adults (capsules).
Additional information
No relevant side effects related to the use of Tasectan® AF have been reported in clinical studies
Consultation with a healthcare professional before using Tasectan® AF is not necessary. However, it is advisable in some cases.
Tasectan® AF is not a pharmacological treatment. If needed, it can be administered concomitantly with another treatment prescribed by a healthcare professional.
Clinical studies and publications, as well as the Summary on Safety and Clinical Performance (SSCP), are available upon request.
Tasectan® AF is a substance-based medical device that holds MDR certification, class III, issued by the NB CE 0476
Clinical Evidence: Clinical trials support this formulation; detailed study data and references are available upon request.
For more information, including clinical trial data and dossier details, please contact us.
CE mark + MDR Class III note